409. Deputy Willie O'Dea asked the Minister for Health further to Parliamentary Question No. 279 of 22 October 2019, if osimertinib for adult patients with locally advanced or metastatic EGFRT790M mutation-positive non-small cell lung cancer will be made available from 1 January 2020; if the HSE senior leadership team has discussed the reimbursement of the drug for adult patients with same subsequent to its decision of 9 July 2019 that it was minded to approve the drug; and if he will make a statement on the matter. [47536/19]

Summary

409. Deputy Willie O'Dea asked the Minister for Health further to Parliamentary Question No. 279 of 22 October 2019, if osimertinib for adult patients with locally advanced or metastatic EGFRT790M mutation-positive non-small cell lung cancer will be made available from 1 January 2020; if the HSE senior leadership team has discussed the reimbursement of the drug for adult patients with same subsequent to its decision of 9 July 2019 that it was minded to approve the drug; and if he will make a statement on the matter. [47536/19]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Reimbursement

  xml · EN · 19 November 2019

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.